Sihuan Pharmaceutical Holdings Group Ltd.

As of December 31, 2025, Sihuan Pharmaceutical Holdings Group Ltd. carries a market capitalization of 11.12B, placing it among publicly traded companies globally. Its enterprise value stands at 8.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sihuan Pharmaceutical Holdings Group Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Sihuan Pharmaceutical Holdings Group Ltd. has 9.04B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Sihuan Pharmaceutical Holdings Group Ltd. maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Sihuan Pharmaceutical Holdings Group Ltd.'s stock has declined approximately 52.35% over the past 52 weeks. The 50-day moving average sits at 0.76, while the 200-day moving average is 1.10.

As of December 31, 2025, Sihuan Pharmaceutical Holdings Group Ltd. holds 4.43B in cash and equivalents against 1.12B in total debt, resulting in a net debt position of -2.87B. Total book value stands at 6.51B, with working capital of 3.30B providing operational flexibility.

Sihuan Pharmaceutical Holdings Group Ltd.'s most recent stock split took place on June 5, 2014 with a 1:2 split ratio.